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Abstract
Background: Pancreatic cancer (PC) has the worst survival of all periampullary cancers. This may relate to
histopathological differences between pancreatic cancers and other periampullary cancers. Our aim was to examine
the distribution and histopathologic features of pancreatic, ampullary, biliary and duodenal cancers resected with a
pancreaticoduodenectomy (PD) and to examine local trends of periampullary cancers resected with a PD.
Methods: A retrospective review of PD between January 2000 and December 2012 at a public metropolitan
database was performed. The institutional ethics committee approved this study.
Results: There were 142 PDs during the study period, of which 70 cases were pre-2010 and 72 post-2010,
corresponding to a recent increase in the number of cases. Of the 142 cases, 116 were for periampullary cancers.
There were also proportionately more PD for PC (26/60, 43% pre-2010 vs 39/56, 70% post-2010, P = 0.005). There
were 65/116 (56%) pancreatic, 29/116 (25%), ampullary, 17/116 (15%) biliary and 5/116 (4%) duodenal cancers.
Nodal involvement occurred more frequently in PC (78%) compared to ampullary (59%), biliary (47%) and duodenal
cancers (20%), P = 0.002. Perineural invasion was also more frequent in PC (74%) compared to ampullary (34%),
biliary (59%) and duodenal cancers (20%), P = 0.002. Microvascular invasion was seen in 57% pancreatic, 38%
ampullary, 41% biliary and 20% duodenal cancers, P = 0.222. Overall, clear margins (R0) were achieved in fewer PC
41/65 (63%) compared to ampullary 27/29 (93%; P = 0.003) and biliary cancers 16/17 (94%; P = 0.014).
Conclusions: This study highlights that almost half of PD was performed for cancers other than PC, mainly
ampullary and biliary cancers. The volume of PD has increased in recent years with an increased proportion being
for PC. PC had higher rates of nodal and perineural invasion compared to ampullary, biliary and duodenal cancers.
Keywords: Pancreatic cancer, Ampullary cancer, Biliary cancer, Duodenal cancer, Periampullary cancer, Margin,
Pancreaticoduodenectomy, Histopathology, Whipple
Background
Pancreaticoduodenectomies (PDs) are performed for re-
sectable periampullary cancers, which are pancreatic,
ampullary, biliary and duodenal cancers. The proportion
of these cancers resected with a PD in contemporary
series is variable. In a recent large three-decade study of
2,564 resected periampullary cancers, by He et al., the
distribution of resected pancreatic, ampullary, biliary
and duodenal carcinomas were 66%, 16%, 12%, and 6%,
respectively [1]. An Australian series by Chen et al. of
96 patients undergoing PD for malignancy found the
proportion of resected pancreatic, ampullary, biliary and
duodenal cancers were 63%, 15%, 9%, and 9%, respect-
ively [2].
Ampullary cancers were historically thought to be an
uncommon tumour amongst patients undergoing PD.
Given that approximately 20% of pancreatic cancers are
amenable to resection compared to over 80% of ampul-
lary cancers, ampullary cancers represent a significant
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proportion of patients undergoing a pancreaticoduode-
nectomy [3]. A recent large Chinese series by Chen et al.
of 501 periampullary cancers found that ampullary carcin-
omas represented the majority of cancers subjected to a
PD at 50%, followed by pancreatic cancer 34%, biliary can-
cer 10% and duodenal cancer 5% [4]. This high incidence
of ampullary cancers in the Chinese series may relate
to geographic differences in the epidemiology of these
cancers.
Pancreatic cancer has a poorer survival compared to
biliary and ampullary cancers and although they are
different histologically, it is unclear whether underlying
tumour behaviour or invasiveness alone contributes to
these differences in survival [5]. Despite the poor sur-
vival with pancreatic cancer, nearly 20% of patients with
resected pancreatic cancer have a chance of long-term
survival [6]. Several studies have shown a higher inci-
dence of nodal, neural and vascular invasion in pancre-
atic cancers compared to ampullary cancers, which may
relate to the differences seen in survival [7].
The aim of this study was to examine the distribution
and histopathologic features of pancreatic, ampullary,
biliary and duodenal cancers resected by PD and re-
ferred for analysis to a single large public metropolitan
laboratory, and also to determine whether there were
changes in trends over time.
Methods
A retrospective review of PD histopathology reports was
performed between January 2000 and December 2012 at
the South Australian (SA) Pathology database at the Royal
Adelaide Hospital. The institutional ethics committee ap-
proved this study. A search of the SA Pathology database
was performed to identify all consecutive PD reports dur-
ing the study period.
The database included demographic data and histo-
pathological reports.
Demographics
The age, gender distribution of the study population and
their cancer subgroups were analysed.
Pathological characteristics
Cancers were identified and subgrouped as pancreatic,
ampullary, biliary and duodenal cancer to identify the
proportions of each cancer resected with a PD. Tumour
size, nodal status, total number of nodes resected, pres-
ence of microvascular or neural invasion was assessed
for each of the tumour subgroups.
Margin assessment
Microscopic margin (R1) involvement was defined as the
presence of microscopic tumour at the mobilization or
transection margins of the surgical specimen as defined
by the International Union Against Cancer [8]. The an-
terior and posterior margins were the margins located
anteriorly and posteriorly as referenced by the pancreas
when lying in its usual anatomic location and are syn-
onymous with the ‘mobilization margins’. The medial
margin or the superior mesenteric vessel margin is that
margin bordered by the uncinate process alongside the
superior mesenteric vessels. The pancreatic neck margin
is the transection margin of the pancreas at the neck of
the pancreas anterior to the porto-mesenteric vein con-
fluence or to the left of this. The medial margin and the
pancreatic neck margin are also known as the ‘transec-
tion margins’.
The proportion of patients with clear margins before
and after 2010 was performed as a subset analysis to as-
sess if these were any different with more recent surgical
practice.
Statistical methods
Statistical methods used in this study are mostly limited
to simple descriptive methods such as chi-squared test
for testing both the 2 × 2 associations and trend test for
proportions [9,10]. Due to the small numbers in three-
and four-way classification, multivariate analysis was not
performed. However, simple two-way cross-tabulation
between cancer type and nodal disease, perineural inva-
sion and vascular invasion were performed to assess for
association.
Multinomial logistic regression between cancer type
and age was carried out to evaluate the age-adjusted ef-
fect on the risk of cancer type. Multinomial regression
was used since the outcome was categorical.
All statistical analyses were performed in STATA version
13 [11]. All P values calculated were two-tailed; the alpha
level of significance was set at 0.05.
Results
Study population
There were 142 PD patients during the study period, of
which 126 were referred from public hospitals (70 from
Royal Adelaide Hospital, 40 from Queen Elizabeth
Hospital and 16 from Lyell McEwin Health Service),
whilst 16 were from private institutions. Seventy PDs
were performed between 2000 and 2009 and 72 between
2010 and 2012. There were 116 PDs performed for pan-
creatic, ampullary, biliary and duodenal adenocarcinoma
and 6 for neuroendocrine and 5 for intraductal mucin-
ous tumours. Of these 116 resections for adenocarcin-
oma, almost half, 56 (48%), was performed between the
periods 2010 to 2012.
Demographics
Of the 116 PDs identified above, there were 67 males
(58%) and 49 females (42%) aged between 26 and 86 years.
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The most common pathology for which a PD was per-
formed was pancreatic cancer (65/116, 56%), followed by
ampullary cancer (29/116, 25%), biliary cancer (17/116,
15%) and duodenal cancer (5/116, 4%) (Table 1).
The median age of all the patients undergoing a PD
for a cancer was 67 years (range 26 to 86). Patients with
pancreatic cancer had a median age of 64 years (range
26 to 81), those with ampullary cancer had a median age
of 69 years (range 42 to 86), biliary cancer median age
66 years (range 55 to 85) and duodenal cancer median
age of 77 years (range 51 to 84).
Pancreatic cancer
There were 65/116 (56%) pancreatic cancers. The me-
dian size of these cancers was 35 mm. The vast majority
of these tumours were node positive (51/65, 78%). The
median number of nodes harvested during a PD was 12
(range 1 to 27).
A clear resection margin was achieved in 41/65 (63%),
with microscopic disease at the margin seen in 24/65
(37%). The anterior margin was involved in 6/24 pa-
tients, posterior margin in 5/24 patients, medial margin
in 12/24 patients, and the neck margin in 5/24 patients
(Table 2).
Prior to 2010, a clear resection margin was achieved in
12/26 (46%) patients, and after 2010, a clear resection
margin was achieved in 26/39 (67%) patients. There was
evidence of microvascular invasion in 37/65 (57%) pa-
tients and perineural invasion in 48/65 (74%) patients.
There was no evidence of nodal, microvascular or
perineural involvement in only 2/65 patients with pan-
creatic cancer.
Ampullary cancers
There were 29/114 (25%) ampullary cancers. The me-
dian size of these cancers was 23 mm. Approximately
half of these tumours were node positive (17/29, 59%).
The median number of nodes harvested was 7.5 (range 1
to 26).
A clear resection margin was achieved in 27/29 (93%),
with microscopic disease at the margin seen in 2/29
(7%). The two patients with involved margin had involve-
ment on the posterior margin in one and the medial mar-
gin in the other.
Prior to 2010, a clear resection margin was achieved in
18/20 (90%), and after 2010, a clear resection margin
was achieved in all nine patients (100%).
There was evidence of microvascular invasion in 11/29
(38%) patients and perineural invasion in 10/29 (34%)
patients.
There was no evidence of nodal, microvascular or peri-
neural involvement in only 5/29 patients with ampullary
cancer.
Biliary cancers
There were 17/114 (15%) biliary cancers. The median
size of these cancers was 27 mm. Approximately half of
these tumours were node positive (8/17, 47%) The me-
dian number of nodes harvested was 12 (range 4 to 30).
A clear resection margin was achieved in 16/17 (94%),
with microscopic disease at the margin seen in one pa-
tient who had involvement of both the anterior and
medial margins.
Prior to 2010, a clear resection margin was achieved in
9/11 (82%), and after 2010, a clear resection margin was
achieved in all six patients (100%).
There was evidence of microvascular invasion in 7/17
(41%) patients and perineural invasion in 10/17 (59%)
patients.
There was no evidence of nodal, microvascular or
perineural involvement in only 1/17 patient with biliary
cancer.
Duodenal cancers
There were 5/114 (4%) duodenal cancers. The median
size of these cancers was 30 mm. One of these tumours
was node positive. The median number of nodes harvested
was 9 (range 2 to 22).
A clear resection margin was achieved in 4/5 (80%)
with microscopic disease at the margin seen in 1/4
(25%) patient. This patient had involvement of both the
anterior and posterior margins.
Prior to 2010, a clear resection margin was achieved in
2/3 (67%), and after 2010, a clear resection margin was
achieved in 2/2 (100%) patients.
There was evidence of microvascular invasion in 1/5
(20%) patient, and perineural invasion in 1/5 patient
(20%).
Table 1 Distribution of tumour pathology, size, nodal, vascular and neural invasion in pancreaticoduodenectomy
specimens
Tumour type n (%) Tumour size median (mm) Nodal involvement n (%) Microvascular invasion Neural invasion
Pancreatic 65 (56%) 35 51 (78%) 37 (57%) 5 S; 9 U 48 (74%) 4 S; 5 U
Ampullary 29 (25%) 23 17 (59%) 11 (38%) 9 U 10 (34%) 7 U
Biliary 17 (15%) 27 8 (47%) 7 (41%) 2 S; 1 U 10 (59%) 1 S; 1 U
Duodenal 5 (4%) 30 1 (20%) 1 (20%) 1 (20%)
S, suspicious; U, unreported.
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There was no evidence of nodal, microvascular or
perineural involvement in 4/5 patients with duodenal
cancer.
Cancer type and histopathological features
There was statistically significant association between
cancer type and the incidence of nodal disease (chi-square,
P value = 0.002) and the incidence of perineural invasion
(chi-square, P value = 0.002). There was no significant as-
sociation between cancer type and the incidence of micro-
vascular invasion (chi-square, P value = 0.222).
Trends before and after 2010
In the 3 years following 2010, there was an increase in
the annual number of PD compared to the preceding
10 years - 70 (7 PD/year) vs 72 (24 PD/year). A chi-
square test for trend in proportions was performed to
test if the change was statistically significant. Results
infer that the trend was statistically significant (P value
for trend being 0.002), thus indicating an increase in
PD.
The proportion of patients with pancreatic cancer fol-
lowing PD also increased significantly from 26/60 (43%)
pre-2010 to 39/56 (70%), P = 0.005. Interesting, there
was an improvement in R0 resection rates in the 3 years
following 2010. A clear margin was achieved in 46% of
patients prior to 2010 and 67% of patients after 2010.
Multinomial logistic regression between cancer type
and age showed that the association between age and
type of cancer was not statistically significant (P values
between 0.22 and 0.36). However, this must be interpreted
with caution due to the low number of cases within the
cancer types.
Discussion
In our cohort of 116 patients, PD was performed for
pancreatic cancer in 56% of patients and ampullary can-
cer in 25%. Whilst the proportion of resected ampullary
cancers is higher than contemporary series from the US,
it is lower than the Chinese series [4]. Pancreatic cancers
in this series had a higher incidence of nodal involve-
ment, microvascular invasion and perineural invasion.
Due to the study being conducted through a pathology
database at a specific hospital site, not all patients would
have been captured from all of the other sites. However,
it was apparent that there was an overall increase in the
proportion of patients with PD for pancreatic cancer in
the later part of our series.
The advent of synoptic reporting will allow us to con-
sistently assess pathological features such as nodal, micro-
vascular and perineural invasion in different cancers and
analyse their prognostic relevance. Earlier reports in this
series had inconsistent reporting of perineural and micro-
vascular invasion, which improved with the introduction
of synoptic reporting.
Ampullary cancers represented a significant proportion
of cancers (29/116, 25%) that were subjected to a PD in
our series, higher than the 16% reported by He et al. and
23% reported by Hatzaras et al.
Fifty-nine percent of patients with ampullary carcin-
oma in our series had lymph node involvement com-
pared to 47% in the series by Brown et al. They showed
that the 5-year survival with ampullary carcinoma was
78% without nodal involvement and 25% with nodal in-
volvement [12]. Survival with ampullary cancer is also
diminished in the presence of vascular invasion and
neural invasion [13].
Patients with ampullary cancers in our series were
slightly older than those with pancreatic cancer. In a his-
torical cohort (1981 to 1997) of ampullary tumours from
our institution, 13/20 patients with ampullary cancer in
that period underwent a PD, and this was the recom-
mended treatment in fit patients [14]. Yeh et al. analysed
their survival of patients under and over the age of 75
undergoing a PD for ampullary cancers and found that
there was no difference in survival or outcomes between
the two age groups [15]. This supports resection for am-
pullary cancers in fit elderly patients.
Pancreatic cancers have the worst survival compared
to other periampullary cancers [16]. In the recent Johns
Hopkins series by He et al., pancreatic cancer had the
worst survival (median survival 19 months, 5-year overall
survival (OS) 18%), followed by bile duct cancer (median
survival 23 months, 5-year OS 27%), ampullary cancer
Table 2 Resection margin status by tumour type
Margin status Pancreatic (n = 65) Ampullary (n = 29) Biliary (n = 17) Duodenal (n = 5)
Clear margin 41 (63%) 27 (93%) 16 (94%) 4 (80 %)
Positive margin 24 (37%) 2 (7%) 1 (6%) 1 (20%)
Anterior margin 6 0 1 1
Posterior margin 5 1 0 1
Medial/SMA margin 12 1 1 0
Pancreatic neck margin 5 0 0 0
R2 (macroscopic margin involvement) 3 0 0 0
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(median survival 47 months, 5-year OS 45%) and duo-
denal cancer (median survival 54 months, 5-year OS
49%) [1].
In our series, patients with pancreatic cancer had the
highest incidence of nodal involvement (78%), perineural
invasion (74%) and microvascular invasion (57%) all of
which have been shown to be poor prognostic features.
The higher incidence of nodal involvement in pancreatic
compared to ampullary cancers has been demonstrated
in several series [1,7,13,17]. In the large series of 1,175
resected pancreatic cancers by Winter et al., the inci-
dence of nodal involvement (78%) and vascular involve-
ment (53%) was similar to our series; however, the
incidence of perineural invasion was much higher in
their series at 91% [18]. In a more recently published
series of 1,822 resected pancreatic cancers by Mayo et al.
there was a 69% incidence of perineural invasion [19]. In
addition to providing an alternate route for metastatic
spread, perineural invasion is involved in pain generation
in patients with pancreatic cancer [20].
Pancreatic cancers had a 37% incidence of microscopic
margin involvement, which was disproportionately
higher than the 6% to 7% seen in both ampullary and
biliary cancers. Our positive resection margin rates are
comparable to an Australian statewide series by Speer
et al. [21]. In our series, a clear margin was achieved in
46% of patients prior to 2010 and 67% of patients after
2010. Changes and improvement in surgical technique
may have accounted for this difference; however, this
study was not designed to explore this.
In the Australian series by Chen et al. the combined
presence of both perineural and lymphovascular inva-
sion following PD reduced the 5-year-survival from 71 %
(when both were absent) to 16% (when both were
present) [2]. In our series, only 2/65 (3%) patients with
pancreatic cancer and 1/17 with biliary cancer had no
evidence of nodal, microvascular or perineural invasion.
In contrast, 5/29 (17%) patients with ampullary cancer
and 4/5 (80%) patients with duodenal cancer had no
nodal, microvascular or perineural invasion. A follow-up
study on survival will evaluate this further.
It may well be that the poorer survival seen in patients
with pancreatic cancer as opposed to other subgroups
undergoing a PD lies in the high incidence of lympho-
vascular and perineural invasion compared to ampullary
cancers as seen in this study. This would be fitting with
Whipple’s hypothesis that pancreatic cancers have a
worse prognosis compared to ampullary cancers because
they exhibit early lymphovascular and perineural inva-
sion [3,22].
The definition of a positive margin in our series was
the presence of cancer to the mobilization surface of the
pancreas (anterior and posterior) or the transection sur-
face (pancreatic neck or medial margin). There are
variable definitions as to what constitutes a positive mar-
gin, and a large range of figures for margin positivity exists
depending on how stringent the pathological definitions
and assessments are [23,24].
In the large series by Winter et al. of 1,175 resected
pancreatic cancers, 42% had a positive margin. Margin
status has been shown to relate to survival outcomes.
Yeo et al. showed in their series of 201 patients that the
actuarial 5-year survival in those with a negative margin
was 26% (median survival 18 months) compared to those
with a positive margin 8% (median survival 10 months)
[25]. Whilst margin positivity appears to be critically im-
portant, not all margins may have a similar impact or
bearing on survival. Delpero et al. reported that whilst a
positive SMA or SMV margin had a significant impact on
progression-free survival, a positive posterior margin had
no impact [26].
A higher incidence of margin positivity is reported de-
pending on the definition used such as the British Royal
College of Pathologists (RCPath) and the Royal College of
Pathologists Australia (RCPA) that regards tumour ≤1 mm
from a pancreatic resection margin as an involved margin
[27,28]. A positive margin using this definition was seen in
109/148 (74%) of patients in the study by Jamieson et al.
[29]. In the study by Hartwig et al., the positive margin rate
was 64% using this revised definition [30].
In our study, of the 24 patients with a positive margin,
half was positive at the medial margin. There were five
positive pancreatic neck margins, and frozen section of
the pancreatic neck margin may reduce this incidence.
In a study by Pang et al. of 101 frozen sections of the
pancreatic neck margin, 19 (19%) were positive. Of these
19, re-resection enabled 16 to have a negative neck mar-
gin, but only seven had no other margin involvement.
Although the authors found that frozen section im-
proved R0 rate by 7%, this did not improve survival [31].
In an era where our understanding of the molecular
basis of disease is increasing, each cancer needs to be
recognised as a distinct entity with its own histomolecular
characteristics. This will enable us to treat each cancer
distinctly as a unique and separate entity. An obvious ex-
ample is that whilst pancreatic cancers invariably have
KRAS mutation in over 90% of these cancers and a higher
incidence of DPC4 inactivation of up to 55%, this is not
seen to the same degree in ampullary or biliary cancers
[32-37]. This has significant bearing on future clinical tri-
als by targeting discrete molecular and genetic aberrancies
within these cancers [38]. KRAS mutation is seen in up to
17% of bile duct cancers and up to 52% of ampullary can-
cers [39,40].
Conclusions
This study highlights that almost half of PD in a single
government-administered large metropolitan database
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are performed for cancers other than pancreatic cancer,
mainly ampullary and biliary cancers. These cancers
need to gain separate attention to pancreatic cancers in
clinical trials as they represent a large proportion of can-
cers resected with a PD. The volume of PD has in-
creased in recent years with an increased proportion
being for PC. PC had higher rates of nodal and perineu-
ral invasion compared to other periampullary cancers.
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